NEW BRUNSWICK, N.J. Drug maker Johnson & Johnson boasted a large drug development pipeline in a statement preceding a meeting with investors Thursday.
The company highlighted early-stage compounds and new regulatory filings in neuroscience, cardiovascular disease, immunology, infectious diseases and cancer, as well as new uses for drugs already on the market.
The company also mentioned the launches of the arthritis and psoriasis drug Simponi (golimumab) and the painkiller Nucynta (tapentadol) and a focus on growing core products like the inflammatory disorder drug Remicade (infliximab), the antipsychotic Risperdal Consta (risperidone) and the attention deficit hyperactivity disorder drug Concerta (methylphenidate hydrochloride).
“We are very optimistic about our future in pharmaceuticals,” J&J worldwide chairwoman of pharmaceuticals Sheri McCoy said in a statement. “We are well-positioned with an industry-leading pipeline, the global reach and financial resources of Johnson & Johnson, a long, rich history in pharmaceuticals and a broad portfolio that is grounded in science and addresses serious unmet needs.”